ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Organon and Co

Organon and Co (OGN)

20.99
-0.36
(-1.69%)
Closed May 25 4:00PM
21.10
0.11
(0.52%)
After Hours: 5:51PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
21.10
Bid
-
Ask
-
Volume
1,043,753
20.90 Day's Range 21.47
10.835 52 Week Range 24.08
Market Cap
Previous Close
21.35
Open
21.44
Last Trade
14
@
20.86
Last Trade Time
Financial Volume
$ 22,102,099
VWAP
21.1756
Average Volume (3m)
2,104,891
Shares Outstanding
255,638,256
Dividend Yield
5.31%
PE Ratio
5.25
Earnings Per Share (EPS)
4
Revenue
6.26B
Net Profit
1.02B

About Organon and Co

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada. Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Organon and Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker OGN. The last closing price for Organon was $21.35. Over the last year, Organon shares have traded in a share price range of $ 10.835 to $ 24.08.

Organon currently has 255,638,256 shares outstanding. The market capitalization of Organon is $5.37 billion. Organon has a price to earnings ratio (PE ratio) of 5.25.

Organon (OGN) Options Flow Summary

Overall Flow

Bullish

Net Premium

28k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

OGN Latest News

L’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)

Shanghai Henlius Biotech, Inc. (2696.HK) et Organon (NYSE : OGN) ont annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) a validé les demandes d’autorisation de mise sur le marché...

Europäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14

Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Arzneimittel-Agentur (EMA) die Zulassungsanträge (MAAs) für HLX14, einen Prolia® und...

欧州医薬品庁(EMA)、ヘンリウスとオルガノンによるProlia ® およびXgeva ® (デノスマブ)バイオシミラー候補HLX14を認証

(ビジネスワイヤ) -- シャンハイ・ヘンリウス・バイオテック(2696.HK)とオルガノン(NYSE:OGN)は、欧州医薬品庁(EMA)が、Prolia®およびXgeva ®(デノスマブ)のバイオシミラーの治験薬であるHLX14の販...

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14...

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.39-1.8147975802721.4921.9820.9150989721.73556306CS
42.6714.487249050518.4321.9818.11219620120.35296676CS
123.620.571428571417.521.9817.25210489118.88258167CS
269.8387.22271517311.2721.9810.835303764316.03711654CS
520.532.5765678172120.5724.0810.835320097816.78355475CS
156-13.1-38.304093567334.239.47510.835254822724.57461239CS
260-13.1-38.304093567334.239.47510.835254822724.57461239CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

OGN Discussion

View Posts
Monksdream Monksdream 5 months ago
OGN not so hot from a chart standpoint
👍️0
LordDarley LordDarley 3 years ago
Looks good.
There is also a very nice analysis on seeking Alpha. Shows pros and cons, and is professional quality IMHO. Much more detail than the Barron's article.
👍️0
DewDiligence DewDiligence 3 years ago
Barron’s bullish on OGN:

https://www.barrons.com/articles/jobs-report-fed-interest-rates-inflation-51622846230 Organon (OGN), which Merck (MRK) jettisoned this past week, could be another winner. This is a classic spinoff situation. Organon is a group of noncore Merck businesses—off-patent drugs sold mainly overseas, biosimilars, and a women’s health business—that may fare better as an independent company.
“You easily can see how this business could have been lost inside of Merck and been undermanaged relative to the rest of the portfolio,” says James Hounsell, a senior research analyst at Smead Capital Management, a Merck shareholder. “That’s when the magic happens with spinoffs.”

The shares trade around $34, giving the company a market value of $8.6 billion, plus about $9 billion of net debt. Merck shareholders received one Organon share for every 10 of Merck. Organon trades for just six times 2020 profits of $5.90 a share. Similar earnings are expected this year.

Organon isn’t as cheap when valued against projected 2021 earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.3 billion, based on its enterprise value of equity value plus net debt. Then, it trades around eight times, in line with mature drug companies.

At a May investor day, Merck projected $6.1 billion to $6.4 billion of 2021 revenue for Organon and annual sales increases in the low- to mid-single digits. The dividend hasn’t been set yet, but based on Organon’s financial guidance, it could be about 3%.

Major drivers for the company are expected to be an implantable women’s contraceptive called Nexplanon and biosimilars, which are generic versions of bioengineered drugs.

“This is a stable, predictable business with low- to mid-single digit growth organically,” Organon CEO Kevin Ali tells Barron’s. He is bullish on the growth outlook for the women’s health business, now about 25% of revenue, plus the opportunity for potential acquisitions.

Given its low price/earnings ratio, Organon has good appreciation potential if it can deliver on its financial goals.
👍️0
DewDiligence DewDiligence 3 years ago
OGN spin-off from MRK begins trading today:

https://www.businesswire.com/news/home/20210602006079/en
👍️0

Your Recent History

Delayed Upgrade Clock